Endotelix Diagnostics Sàrl

Solutions for Antiphospholipid Syndrome

Swiss Startup - Endotelix Diagnostics Main Image

Swiss Startup - Endotelix Diagnostics Product Image

Swiss Startup - Endotelix Diagnostics Team Image

Swiss Startup - Endotelix Diagnostics Additional Image

Endotelix is a spin-off from the University of Geneva and dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome including diagnostic tests and treatment options. We are currently developing a new diagnostic test to measure the circulating levels of antiphospholipid antibodies (aPL) as a rapid test (LFA-like). It allows the measuring of anti-ß2GP1 IgG and IgM. This diagnostic test is more sensitive and faster than the current assays. We have also developed an ELISA test for hospital and Research Use Only.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

16.03.2023

FIF Funding for three new Geneva projects (startupticker.ch)

28.01.2020

Diagnostic and cleantech start-ups get the first CHF150,000 “Kicks” of 2020 (startupticker.ch)

31.01.2024

Seed Funding Round

30.06.2023

Full Clinical Validation of Endotelix's Technology

No Jobs

Videos

Endotelix Diagnostic Teaser

A Kickers' World, Episode 5 Endotelix CEO Karim Brandt

Documents

Executive Summary

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (150'000) 2020

Website